BeOne Medicines Expands BRUKINSA Access for CLL Patients
SAN CARLOS, Calif. & SEATTLE, Aug. 18, 2026 BeOne Medicines Ltd., together with the BeOne Care Foundation and The...
CLL
Advertisement
Sanofi’s MenQuadfi Receives EU Approval for Infants From Six Weeks of Age
PARIS, Aug. 4, 2026 Sanofi announced that the European Commission (EC) has approved an expanded indication for MenQuadfi® (Meningococcal...
Nurix Therapeutics Enrolls First Patient in Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg
BRISBANE, Calif., Aug. 4, 2026 Nurix Therapeutics, Inc. announced the enrollment of the first patient in the registrational Phase...
CREATE, Monash Partner to Advance In Vivo CAR-T Platform
CAMBRIDGE, Mass., July 31, 2026 CREATE Medicines has announced a strategic research collaboration and exclusive worldwide licensing agreement with...
Curis Advances TakeAim CLL Trial with First Patients Dosed
LEXINGTON, Mass., July 30, 2026 Curis, Inc. has reached an important clinical milestone by successfully dosing the first five...
Advertisements
Nurix and Roche Complete Strategic Oncology Collaboration
Brisbane, California, USA | July 21, 2026 Nurix Therapeutics announced the official closing of its previously announced global collaboration...
Curis Achieves Early Enrollment in Phase 2 CLL Trial
LEXINGTON, Mass., July 6, 2026 Curis, Inc. announced an important enrollment milestone for its Phase 2 TakeAim CLL clinical...
Lilly Jaypirca CHMP Backs EU Approval for CLL Treatment
INDIANAPOLIS, June 26, 2026 Eli Lilly and Company announced that the European Medicines Agency’s Committee for Medicinal Products for...
Lilly’s Jaypirca Reduces Risk of Disease Progression or Death by 45% in CLL/SLL
INDIANAPOLIS, Indiana, June 14, 2026 Eli Lilly and Company announced compelling results from the pivotal Phase 3 BRUIN CLL-322...
AbbVie Reports 9-Year VENCLEXTA Data in First-Line CLL
NORTH CHICAGO, Ill., June 12, 2026 AbbVie announced new long-term clinical results from the Phase 3 CLL14 trial at...
Advertisement
